ATAI Life Sciences N.V.
Open
$4.04
Prev. Close
$4.04
High
$4.05
Low
$4.04
Market Snapshot
$1.5B
-2.3
-0.93
$308K
99
Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York City, New York and currently employs 99 full-time employees. The company went IPO on 2021-06-18. The Company’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (R-MDMA HCI) for social anxiety disorder. The firm is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. BPL-003 is a proprietary synthetic intranasal formulation of mebufotenin benzoate being developed as a potential treatment for people living with TRD. VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with TRD. EMP-01 is an oral formulation of R-MDMA, being developed as a potential treatment for people living with social anxiety disorder.
emptyResult
Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York City, New York and currently employs 99 full-time employees. The company went IPO on 2021-06-18. The Company’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (R-MDMA HCI) for social anxiety disorder. The firm is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. BPL-003 is a proprietary synthetic intranasal formulation of mebufotenin benzoate being developed as a potential treatment for people living with TRD. VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with TRD. EMP-01 is an oral formulation of R-MDMA, being developed as a potential treatment for people living with social anxiety disorder.
Recently from Cashu
Deutsche Bank Backs Atai Life Sciences for Growth in Psychedelic Medicine Market
Atai Life Sciences Positioned for Growth in Psychedelic Medicine Deutsche Bank recently initiates coverage of Atai Life Sciences, signaling strong confidence in the company’s future in the burgeoning…
Please provide the content or details you would like summarized regarding ATAI Life Sciences N.V.
Please provide the specific content or details regarding ATAI Life Sciences N.V. that you would like summarized. Once I have that information, I can create an article in the format you requested.
Helus Pharma's Breakthrough HLP004 Promises New Hope for Generalized Anxiety Disorder Treatment
### Innovative Advancements in Mental Health Treatment ATAI Life Sciences N.V. focuses on developing novel therapeutics for mental health conditions and might find significant relevance in the recent…
Helus Pharma Reports Positive Phase 2 Results for GAD Treatment with HLP004
Helus Pharma Takes a Significant Step Forward in Mental Health Treatment Helus Pharma is gaining attention for its innovative approach to tackling generalized anxiety disorder (GAD) through its promis…